NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Breast Cancer and the NCCN Drugs & Biologics Compendium (NCCN Compendium™) Chapter for Breast Cancer. The NCCN Guidelines™ for Breast Cancer are currently available as Version 2.2010.
The update to the NCCN Guidelines™ for Breast Cancer includes a new footnote added to page BINV-17, footnote h, which states "Limited studies document a progression free survival advantage of adding trastuzumab or lapatinib to aromatase inhibition in postmenopausal patients with ER-positive, HER2-positive disease. However, no overall survival advantage has been demonstrated."
The discussion section of the NCCN Guidelines for Breast Cancer and the NCCN Compendium™ Chapter for Breast Cancer have also been updated.